Traverse Biotech has been awarded a Phase I SBIR grant from the National Cancer Institute to develop targeted immunotherapy for selected solid tumors

NEW YORK, Oct. 18, 2023 /PRNewswire/ — Traverse Biotech, Inc announced today that the National Cancer Institute (NCI) of the National Institutes of Health has awarded them a Small Business Innovation Research (SBIR) Phase 1 Grant to fund the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC), the most … Read more